Image-guided radiotherapy developer ViewRay is touting research from the recent American Association of Physicists in Medicine (AAPM) annual meeting that features clinical experience with the company's MRIdian system.
The research includes the first data from the company's MRIdian linear accelerator (linac) technology, MRIdian Linac, which is currently under development.
Researchers from the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis and the University of California, Los Angeles (UCLA) discussed the design and technical characteristics of the MR-guided linac and summarized data from recent testing performed in ViewRay's Mountain View, CA, facility.
The AAPM speakers highlighted ViewRay's magnetic and radiofrequency shielding technology that ensures minimal interaction between the linear accelerator and the MRI magnetic field. Quantitative data were presented demonstrating the ability of the system to image and deliver radiation simultaneously, the firm said.
The UCLA researchers developed a diffusion MRI technique on MRIdian Linac that quantifies tissue density inside tumors to gauge their response to radiation. The research presented demonstrates MRIdian's capabilities for on-table anatomical and biological imaging during the course of radiation therapy, ViewRay added.
The MRIdian Linac technology is presently available for nonclinical research use only. ViewRay expects to complete its U.S. Food and Drug Administration (FDA) and European CE Mark submissions for the MRIdian Linac in the second half of this year.
